Genomics Core
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1U19AI168631-01
Grant search
Key facts
Disease
COVID-19, DengueStart & end year
20222027Known Financial Commitments (USD)
$283,216Funder
National Institutes of Health (NIH)Principal Investigator
Robert SebraResearch Location
United States of AmericaLead Research Institution
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
GENOMICS CORE D PI: Dr. Sebra PROJECT SUMMARY Recent advances in genomics technology and associated data analysis methods have provided a framework to interrogate the human host response to vaccination and the dynamic interplay between host and pathogen during viral infection at an unprecedented resolution. The integration of molecular and cellular data alongside clinical metadata and serologic data nucleates the potential to identify signatures of viral immunity outcomes by characterizing changes in innate immunity before and after vaccination. However, no single technology is sufficient to address the multitude of open questions raised by deep molecular immune profiling, necessitating an integrated approach for profiling immunity and vaccine response. Analysis of PBMCs and histocultures across VIVA projects with a variety of cutting-edge and custom high throughput, molecular and high-resolution multi-omics technologies will provide the best database for vaccine immune responses across these systems. The VIVA Genomics Core D aims to leverage a data generation technology suite inclusive of bulk RNAseq, serologic data, single cell CITEseq, CyTOF, spatial transcriptomics, viral genomics and multi-scale computational approaches for the comprehensive characterization of immune response to predict vaccine outcomes. Using the integration of these data, Core D will deliver multi-omics data generation and quality control for seamless analysis, integration and annotation with the Genomics Data Analysis and Management Core E across VIVA projects including the Immune/Clinical Core, Project 1 (SARS-CoV-2), Project 2 (seasonal influenza), Project 3 (tetravalent DENV). Core D will serve as an invaluable resource for the VIVA HIPC team coupling molecular data generation and Core E data driven approaches to foster technology refinement and development and promote collaboration between VIVA projects.